CASI PharmaceuticalsFRA:ENM 29 Gross Margin % is 51.13% as of Dec. 2025, which is 5% above its 10-year median of 48.65. GuruFocus rates FRA:ENM with a GF Score™ of 29/100 and a GF Value™ of €11.74. The stock has 5 warning signs investors should review. Among 732 Biotechnology companies, CASI Pharmaceuticals ranks worse than 61.34% on this metric.
The historical rank and industry rank for CASI Pharmaceuticals's Gross Margin % or its related term are showing as below:
FRA:ENM'
s Gross Margin % Range Over the Past 10 Years
Min: 4.74 Med: 48.65 Max: 63.28
Current: 48.65
During the past 13 years, the highestGross Margin % of CASI Pharmaceuticals was 63.28%. The lowest was 4.74%. And the median was 48.65%.
FRA:ENM's Gross Margin % is ranked worse than 61.34% of 732
companies
in the Biotechnology industry
Industry Median: 60.91
vs FRA:ENM: 48.65
CASI Pharmaceuticals had a gross margin of 51.13% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for CASI Pharmaceuticals was 0.20% per year.
CASI Pharmaceuticals (FRA:ENM) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
CASI Pharmaceuticals had a gross margin of 51.13% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
CASI Pharmaceuticals Gross Margin % Related Terms
CASI Pharmaceuticals Gross Margin % Historical Data
* Premium members only.
The historical data trend for CASI Pharmaceuticals's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:ENM vs ITRMF, OGEN, AZTR: Gross Margin % Comparison
For the Biotechnology subindustry, CASI Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CASI Pharmaceuticals Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where CASI Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
CASI Pharmaceuticals (FRA:ENM) has a Gross Margin % of 51.13% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on CASI Pharmaceuticals and its competitors. This is near median its historical median of 48.65. Over the past decade, CASI Pharmaceuticals' Gross Margin % has ranged from 4.74 to 63.28. According to the industry distribution chart, CASI Pharmaceuticals ranks #449 out of 732 companies in the Biotechnology industry, placing it in the top 61.3%.
Is CASI Pharmaceuticals' Gross Margin % too high?
CASI Pharmaceuticals' current Gross Margin % of 51.13% is near median its 10-year median of 48.65. Over the past 10 years, this metric has ranged from a low of 4.74 to a high of 63.28. The Biotechnology industry median Gross Margin % is 60.91. CASI Pharmaceuticals' value of 51.13% is 16.1% below this industry median. Based on the distribution chart, CASI Pharmaceuticals ranks #449 out of 732 companies in the Biotechnology industry, which is below the industry midpoint. Overall, CASI Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does CASI Pharmaceuticals' Gross Margin % compare to ITRMF and OGEN?
According to the Biotechnology industry distribution chart, CASI Pharmaceuticals ranks #449 out of 732 companies for Gross Margin %. This places CASI Pharmaceuticals in the lower half of its industry. The industry median Gross Margin % is 60.91. CASI Pharmaceuticals' value of 51.13% is 16.1% below this benchmark. Historically, CASI Pharmaceuticals' own Gross Margin % has ranged from 4.74 to 63.28 over the past decade. While the company's 10-year median is 48.65 vs. the industry median of 60.91, CASI Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CASI Pharmaceuticals's current Gross Margin % of 51.13% is 16.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on CASI Pharmaceuticals and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CASI Pharmaceuticals's current Gross Margin % is 51.13%, which is near median its own 10-year median of 48.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CASI Pharmaceuticals stock overvalued right now?
CASI Pharmaceuticals (FRA:ENM) has a current Gross Margin % of 51.13%. The stock's GF Value™ is €11.74, compared to a current price of €1.54 — trading 86.9% below its estimated fair value. The current Gross Margin % is 51.13%, which is near median its 10-year median of 48.65 and 16.1% below the Biotechnology industry median of 60.91. CASI Pharmaceuticals' overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For CASI Pharmaceuticals (FRA:ENM), the current Gross Margin % is 51.13% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CASI Pharmaceuticals (FRA:ENM) Overvalued in 2026?
Based on GuruFocus' analysis, CASI Pharmaceuticals stock appears to be undervalued.
The current stock price of €1.54 is trading 86.9% below its estimated GF Value™ of €11.74.
Key valuation signals for FRA:ENM:
Gross Margin %: 51.13% (near median its 10-year median of 48.65)
GF Value™: €11.74 vs. price of €1.54 (86.9% below fair value)
Industry Position: 16.1% below the Biotechnology median (#449 of 732)
No single metric tells the full story. See the FRA:ENM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.
29GF Score
Get the complete analysis for FRA:ENM
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ENM has been successfully added to your 
